An Australian stem cell and regenerative medicine company

December 07, 2021

A New Kid on the Block

Another, long-established company has been the poster child for stem cell therapy however, there’s several smaller and promising regenerative medicine companies that are doing things differently and making rapid progress. And this includes Cynata addressing the complexities and challenges of manufacturing MSCs at a commercial scale, producing essentially infinite quantities of consistent and potent MSCs from a single donor from a single blood donation.

Read Article

November 09, 2021

Call for osteoarthritis trial enrolments

As we experience the return of many freedoms across Victoria and NSW, many of us are busily scheduling in time with friends/family, eating out, hair and other appointments etc. Professor David Hunter and Dr Ross Macdonald are encouraging those suffering from OA to consider enrolling for the ongoing osteoarthritis clinical trial.

Read Article

October 04, 2021

New Strategic Partnership with Fujifilm

Cynata and Fujifilm have entered a new and exciting strategic partnership agreement which includes detailed and agreed core terms for Fujifilm to provide clinical and commercial manufacturing services for, and supply of its Cymerus MSC products. BioWorld covered this, and Cynata’s quarter of milestones in depth here (subscriber only content)

Read Article

Read More Here

September 28, 2021

Leading peer-reviewed journal Cytotherapy publishes Cymerus™ MSC paper by Associate Professor James Chong

The paper, which summarises the results of studies led by Associate Professor James Chong (Westmead Institute for Medical Research, Sydney), validates the importance of Cymerus MSCs in treating serious and debilitating diseases and provides further recognition of Cynata’s advanced technology.

Read Article

August 13, 2021

Deal signed with TekCyte for its wound dressing technology

Cynata has signed a worldwide licence agreement with TekCyte Pty Ltd for TekCyte’s novel wound dressing technology for use in Cynata’s upcoming diabetic foot ulcer trial (short scroll down) 

Read Article